| Not Yet Recruiting | Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML NCT07508982 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults NCT07516353 | Dana-Farber Cancer Institute | N/A |
| Not Yet Recruiting | Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML NCT07490288 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Recruiting | MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan a NCT07493538 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Not Yet Recruiting | Safety and Efficacy of CLL1 CAR-T Followed by Allogeneic Hematopoietic Stem Cell Transplantation in the Treatm NCT07342244 | Donghua Zhang | N/A |
| Recruiting | Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML NCT06611839 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Recruiting | A Long Term Follow-up Study of TScan TCR-T Products NCT06976736 | TScan Therapeutics, Inc. | — |
| Not Yet Recruiting | QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS) NCT07131085 | Anhui Provincial Hospital | Phase 1 |
| Recruiting | Leptin: A Marker for AML Chemo-Sensitivity NCT07163728 | Fujian Medical University Union Hospital | — |
| Recruiting | A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyc NCT06973668 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT NCT07126782 | Institute of Hematology & Blood Diseases Hospital, China | EARLY_Phase 1 |
| Recruiting | Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients Wi NCT06717958 | Technische Universität Dresden | Phase 2 |
| Recruiting | Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation NCT06972641 | Ruijin Hospital | Phase 2 / Phase 3 |
| Not Yet Recruiting | Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT. NCT06946602 | Peking University People's Hospital | N/A |
| Recruiting | UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy NCT06047886 | University of Alabama at Birmingham | Phase 1 |
| Recruiting | A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malign NCT07347171 | Cullgen (Shanghai),Inc | Phase 1 |
| Recruiting | CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) NCT06834282 | CERo Therapeutics Holdings, Inc. | Phase 1 |
| Not Yet Recruiting | Relation of C-reactive Protein/ Albumin Ratio and Coagulation Profile in Acute Myeloid Leukemia Patients NCT06714071 | Assiut University | — |
| Recruiting | HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML NCT06744556 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1- NCT06744504 | Institute of Hematology & Blood Diseases Hospital, China | Phase 3 |
| Withdrawn | Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML NCT04973618 | Aptevo Therapeutics | Phase 1 |
| Not Yet Recruiting | Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk A NCT06643195 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Not Yet Recruiting | Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With NCT06758726 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Active Not Recruiting | ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive NCT06664879 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Revumenib in Combination With 7+3 + Midostaurin in AML NCT06313437 | Richard Stone, MD | Phase 1 |
| Withdrawn | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs NCT04985357 | Travera Inc | — |
| Recruiting | Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML NCT06741722 | Beijing 302 Hospital | Phase 2 |
| Recruiting | The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation NCT06561880 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Recruiting | Intermediate-dose HAD Regimen for CEBPA Double-mutated AML NCT06529250 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Recruiting | Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia NCT06386302 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Recruiting | Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML NCT06420063 | Essen Biotech | Phase 1 / Phase 2 |
| Not Yet Recruiting | Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia NCT06469047 | Second Hospital of Shanxi Medical University | — |
| Recruiting | Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant NCT06158828 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Recruiting | A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS NCT06731699 | Chengdu FenDi Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia NCT06265545 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Recruiting | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT06001788 | Kura Oncology, Inc. | Phase 1 |
| Enrolling By Invitation | Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) NCT06499025 | BGI, China | EARLY_Phase 1 |
| Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801 | Children's Hospital Medical Center, Cincinnati | — |
| Recruiting | Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML NCT06156579 | University Hospital Tuebingen | Phase 2 |
| Completed | Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers NCT06399315 | Lomond Therapeutics Holdings, Inc. | Phase 1 |
| Not Yet Recruiting | A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-ind NCT05875649 | Nanfang Hospital, Southern Medical University | — |
| Active Not Recruiting | A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD NCT05199051 | Centre Antoine Lacassagne | Phase 2 |
| Recruiting | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies NCT05735717 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabi NCT05796570 | Franziska Wachter | Phase 2 |
| Recruiting | Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results NCT05736978 | Shanghai Tong Ren Hospital | Phase 2 |
| Unknown | NKG2D CAR-NK & r/rAML NCT05734898 | Zhejiang University | N/A |
| Unknown | To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS NCT05740917 | Xuanzhu Biopharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | CC-486 and Venetoclax for Acute Myeloid Leukemia NCT05287568 | University of Colorado, Denver | Phase 1 |
| Active Not Recruiting | Venetoclax in Patients With MDS or AML in Relapse After AHSCT NCT05226455 | Groupe Francophone des Myelodysplasies | Phase 1 / Phase 2 |
| Recruiting | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies NCT05476770 | Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 |
| Recruiting | A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Tra NCT05473910 | TScan Therapeutics, Inc. | Phase 1 |
| Terminated | Psychological Mobile App for Patients With AML NCT05501171 | Massachusetts General Hospital | N/A |
| Unknown | Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML NCT05473221 | Zhejiang University | Phase 1 |
| Unknown | Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML NCT05463640 | Zhejiang University | Phase 1 |
| Unknown | Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML NCT05467254 | Zhejiang University | Phase 1 |
| Unknown | Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML NCT05467202 | Zhejiang University | Phase 1 |
| Recruiting | Registry of Patients Having Received oNKord® NCT05290662 | Glycostem Therapeutics BV | — |
| Active Not Recruiting | A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure NCT05285813 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Diagnosis and Treatment of Periodontal Disease in Patients With AML NCT04530695 | Masonic Cancer Center, University of Minnesota | N/A |
| Unknown | Universal CAR-γδT Cell Injection in the AML Patients NCT05388305 | Hebei Senlang Biotechnology Inc., Ltd. | N/A |
| Recruiting | Cardioprotection in AML NCT04977180 | University of Virginia | Phase 2 |
| Active Not Recruiting | GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG NCT05153226 | DKMS gemeinnützige GmbH | Phase 3 |
| Unknown | Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies NCT05239689 | Zhejiang University | EARLY_Phase 1 |
| Unknown | Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies NCT05252572 | Zhejiang University | EARLY_Phase 1 |
| Withdrawn | Study to Assess an Interphase Cycle With Flotetuzumab. NCT05063123 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 2 |
| Completed | Drug-screening in AML at Relapse for Targeted Treatment NCT05732688 | Insel Gruppe AG, University Hospital Bern | N/A |
| Terminated | NK Cell Therapy for AML NCT05256277 | Zhejiang University | Phase 1 |
| Unknown | Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis NCT05062278 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 |
| Completed | Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML NCT05048615 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 |
| Completed | ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML NCT04857645 | Groupe Francophone des Myelodysplasies | Phase 2 |
| Recruiting | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors NCT04686682 | Jacobio Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS NCT05175508 | The First Affiliated Hospital of Soochow University | Phase 2 / Phase 3 |
| Active Not Recruiting | A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML NCT04730258 | Treadwell Therapeutics, Inc | Phase 1 / Phase 2 |
| Unknown | Donor-derived CAR-T Cells in the Treatment of AML Patients NCT04766840 | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 |
| Unknown | The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remiss NCT05339204 | National Research Center for Hematology, Russia | N/A |
| Unknown | Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transp NCT04796441 | Hebei Senlang Biotechnology Inc., Ltd. | N/A |
| Unknown | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS NCT04358393 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Unknown | NK Cell Therapy Recurrent/Refractory Elderly AML NCT04599452 | The Second Hospital of Shandong University | Phase 1 / Phase 2 |
| Recruiting | Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders NCT04644016 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysp NCT04443751 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | Haplo Peripheral Blood Sct In GVHD Prevention NCT04473911 | Zachariah Michael DeFilipp | Phase 1 |
| Terminated | Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia NCT04425655 | University of California, San Diego | Phase 2 |
| Recruiting | Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML NCT04365179 | Immune System Key Ltd | Phase 1 |
| Terminated | A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML NCT05933070 | Inmune Bio, Inc. | Phase 1 |
| Withdrawn | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML a NCT04128020 | Sherif Farag | Phase 1 |
| Terminated | Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib NCT04079738 | H Scott Boswell | Phase 1 / Phase 2 |
| Recruiting | Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML NCT04061239 | GWT-TUD GmbH | Phase 2 |
| Completed | CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS NCT04017546 | Cyclacel Pharmaceuticals, Inc. | Phase 1 |
| Completed | Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia NCT03844997 | Sudipto Mukherjee, MD, PhD, MPH | Phase 1 / Phase 2 |
| Unknown | Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML) NCT04187495 | Maxinovel Pty., Ltd. | Phase 1 |
| Recruiting | A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Tr NCT03739502 | University of Rochester | Phase 2 |
| Unknown | Study of APVO436 in Patients With AML or MDS NCT03647800 | Aptevo Research and Development LLC | Phase 1 |
| Withdrawn | Epacadostat, Cladribine and Cytarabine (ECC) in AML NCT03491579 | Insel Gruppe AG, University Hospital Bern | Phase 1 |
| Terminated | Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias NCT03761069 | PTC Therapeutics | Phase 1 |
| Completed | DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 NCT03466320 | Celyad Oncology SA | Phase 1 / Phase 2 |
| Withdrawn | Epacadostat, Idarubicin and Cytarabine (EIC) in AML NCT03444649 | Insel Gruppe AG, University Hospital Bern | Phase 1 |
| Terminated | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractor NCT03465540 | Amgen | Phase 1 |
| Completed | Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T) NCT03585517 | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 |
| Unknown | Italian Non-Interventional Study of FLT3 Mutated AML Patients NCT03547258 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | — |
| Completed | Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS NCT03459859 | Justin Watts, MD | Phase 1 |
| Unknown | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS NCT03855371 | Ruijin Hospital | Phase 1 |
| Completed | Haploidentical Donor vs mMUD in Hematological Malignancies NCT03275636 | DKMS gemeinnützige GmbH | Phase 2 / Phase 3 |
| Terminated | The Mutation Profile and Prognosis in AML With IDH1/2 Mutation NCT07004816 | Institute of Hematology & Blood Diseases Hospital, China | — |
| Completed | Ascorbic Acid Levels in MDS, AML, and CMML Patients NCT03526666 | Van Andel Research Institute | — |
| Unknown | Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD NCT03135054 | The University of Hong Kong | Phase 2 |
| Completed | Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leuke NCT03118466 | Massachusetts General Hospital | Phase 2 |
| Withdrawn | iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML NCT03138395 | University of Florida | — |
| Completed | Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying NCT03170895 | The University of Hong Kong | Phase 2 |
| Completed | CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute NCT02995655 | Washington University School of Medicine | Phase 1 |
| Recruiting | Familial Investigations of Childhood Cancer Predisposition NCT03050268 | St. Jude Children's Research Hospital | — |
| Enrolling By Invitation | Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia NCT03031249 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Active Not Recruiting | Efficacy and Safety of Chidamide in CBF Leukemia NCT03031262 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Withdrawn | Efficacy of Decitabine in Clearance of MRD NCT03021395 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Active Not Recruiting | Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML NCT03021330 | Institute of Hematology & Blood Diseases Hospital, China | Phase 3 |
| Withdrawn | Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia NCT02905994 | Massachusetts General Hospital | Phase 1 |
| Unknown | Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AML NCT02888522 | University Hospital, Caen | — |
| Unknown | Chidamide Plus DCAG for Relapsed/Refractory AML NCT02886559 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leu NCT02665065 | Actinium Pharmaceuticals | Phase 3 |
| Terminated | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Ac NCT02795520 | OncoTherapy Science, Inc. | Phase 1 / Phase 2 |
| Completed | VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 Years NCT02606825 | PETHEMA Foundation | — |
| Completed | A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML NCT02403310 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Unknown | Epidemiologic Registry PETHEMA LMA 2015 NCT02607059 | PETHEMA Foundation | — |
| Terminated | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations NCT02418000 | Spirita Oncology, LLC | Phase 1 / Phase 2 |
| Completed | Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML NCT02662647 | Chinese PLA General Hospital | Phase 2 |
| Active Not Recruiting | Incidence and Risk Factors for the Development of Invasive Fungal Infection in Patients Diagnosed With Acute M NCT07060612 | Instituto de Investigacion Sanitaria La Fe | — |
| Completed | A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acu NCT02287233 | AbbVie | Phase 1 / Phase 2 |
| Terminated | Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia NCT02221505 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Photochemotherapy and Graft-versus-leukemia in Acute-leukemia NCT02631993 | Karolinska University Hospital | — |
| Unknown | Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Pos NCT02261779 | Martin-Luther-Universität Halle-Wittenberg | Phase 1 / Phase 2 |
| Completed | Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies NCT02193958 | Fujifilm Pharmaceuticals U.S.A., Inc. | Phase 1 / Phase 2 |
| Terminated | Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) NCT02152956 | MacroGenics | Phase 1 / Phase 2 |
| Completed | (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia NCT02039726 | Daiichi Sankyo | Phase 3 |
| Completed | Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial NCT02160600 | All India Institute of Medical Sciences | N/A |
| Completed | A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) NCT01994837 | AbbVie | Phase 2 |
| Completed | Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion f NCT01690507 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Completed | Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients NCT02575963 | Actinium Pharmaceuticals | Phase 1 / Phase 2 |
| Terminated | Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients NCT01570465 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Terminated | FLT-PET Imaging for MDS NCT01535456 | University of Wisconsin, Madison | N/A |
| Completed | A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors NCT01449058 | Array BioPharma | Phase 1 |
| Terminated | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives NCT01532635 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Epidemiologic Registry PETHEMA LMA 2013 NCT02006004 | PETHEMA Foundation | — |
| Completed | POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients NCT01319864 | Seattle Children's Hospital | Phase 1 |
| Completed | Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients NCT01149408 | University of Utah | Phase 1 |
| Unknown | Rapid Profiling of Bone Marrow, at Presentation and After 5 Days of Induction Therapy NCT01268800 | Rambam Health Care Campus | — |
| Completed | SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) NCT01261312 | Astex Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Terminated | LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) NCT01198054 | PETHEMA Foundation | Phase 4 |
| Completed | Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD NCT03622541 | The University of Hong Kong | Phase 2 |
| Completed | Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies NCT01204164 | Tragara Pharmaceuticals, Inc. | Phase 1 |
| Completed | Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) NCT01184898 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | N/A |
| Completed | Non-interventional Study With Azacitidin (Vidaza®) NCT01192945 | iOMEDICO AG | — |
| Completed | Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation NCT01188174 | Nantes University Hospital | Phase 2 |
| Completed | Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission NCT01096602 | Beth Israel Deaconess Medical Center | Phase 2 |
| Terminated | A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell (AHSC) Transplantation for NCT00808080 | Thomas A. Lane, MD | Phase 1 / Phase 2 |
| Completed | Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) NCT01019317 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT NCT01012492 | Boston Children's Hospital | Phase 2 |
| Completed | Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed NCT00780598 | Chroma Therapeutics | Phase 2 |
| Completed | Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients NCT00863148 | Nantes University Hospital | Phase 2 |
| Completed | A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic NCT00964873 | Synta Pharmaceuticals Corp. | Phase 1 |
| Completed | Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplast NCT00887068 | M.D. Anderson Cancer Center | Phase 3 |
| Completed | STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders NCT00858572 | Synta Pharmaceuticals Corp. | Phase 1 |
| Completed | Umbilical Cord Blood Transplant for Hematological Malignancies NCT00891592 | University of Pennsylvania | Phase 1 |
| Completed | Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function NCT00652626 | Celgene | Phase 1 |
| Unknown | Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) NCT00815568 | Samsung Medical Center | Phase 2 |
| Completed | Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML) NCT00684918 | Gemin X | Phase 2 |
| Completed | Evaluation of Formin Gene Status and Expression in Myeloproliferative and Myelodysplastic Disorders NCT00687414 | Corewell Health West | — |
| Completed | Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant NCT00684008 | Cytheris, Inc. | Phase 1 |
| Completed | Phase I Study in RAD 001 Patients With Relapse AML NCT01074086 | French Innovative Leukemia Organisation | Phase 1 |
| Completed | Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies NCT00533078 | Insel Gruppe AG, University Hospital Bern | Phase 2 |
| Completed | Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) NCT00542971 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 NCT00761449 | Nordic MDS Group | Phase 2 |
| Completed | Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia NCT06211452 | Grupo Argentino de Tratamiento de la Leucemia Aguda | Phase 3 |
| Completed | Sirolimus in Combination With MEC in High Risk Myeloid Leukemias NCT00780104 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD NCT00539695 | Baylor College of Medicine | Phase 2 |
| Completed | A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status NCT00462761 | Daiichi Sankyo | Phase 1 |
| Completed | Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML) NCT00422591 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies NCT00405743 | Clavis Pharma | Phase 1 / Phase 2 |
| Terminated | Study of XL999 in Patients With Acute Myeloid Leukemia (AML) NCT00322673 | Symphony Evolution, Inc. | Phase 2 |
| Completed | CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation NCT00333190 | Dana-Farber Cancer Institute | N/A |
| Completed | Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML) NCT00744081 | Goethe University | Phase 2 |
| Completed | High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML) NCT00707408 | Nantes University Hospital | Phase 2 |
| Completed | Study of Bexarotene in Patients With Acute Myeloid Leukemia NCT00316030 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Terminated | Post Transplant Donor Lymphocyte Infusion NCT00167180 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of He NCT00533923 | Beth Israel Deaconess Medical Center | Phase 2 |
| Completed | Treatment Outcome in Elderly Patients NCT00700544 | University Hospital, Grenoble | Phase 3 |
| Completed | DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML NCT00589082 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 3 |
| Terminated | Stem Cell Transplant for Hematological Malignancy NCT00176930 | Masonic Cancer Center, University of Minnesota | N/A |
| Completed | Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic NCT00013533 | National Cancer Institute (NCI) | EARLY_Phase 1 |
| Terminated | Stem Cell Transplantation for Hematological Malignancies NCT00176839 | Masonic Cancer Center, University of Minnesota | Phase 2 / Phase 3 |
| Completed | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders NCT00636909 | Beth Israel Deaconess Medical Center | Phase 2 |
| Completed | Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders NCT00511537 | University of California, San Francisco | — |
| Completed | Induction With or Without Granulocyte Colony-Stimulating Factor in AML Transplantation in AML NCT00820976 | Turkish Leukemia Study Group | Phase 3 |
| Completed | Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia NCT00167167 | Masonic Cancer Center, University of Minnesota | N/A |
| No Longer Available | Flotetuzumab Expanded Access Program NCT04678466 | MacroGenics | — |
| No Longer Available | Individual Patient Expanded Access Gilteritinib (ASP2215) NCT03315299 | Etan Orgel | — |